PF-06252616 Uses, Dosage, Side Effects and more
PF-06252616 is under investigation in clinical trial NCT01616277 (A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects).
Trade Name | PF-06252616 |
Generic | Domagrozumab |
Domagrozumab Other Names | Domagrozumab, PF-06252616 |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | January 7, 2025 at 1:49 am |